MedTrace Logo

Cognitive Biases Modification Treatment for Social Anxiety

NCT01503151 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2014-12-02

No results posted yet for this study

Summary

Adults with Social Phobia will be randomly assigned to either an attention bias modification treatment, interpretation bias modification treatment, both, or a placebo control condition not designed to change cognitive bias patterns.

Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social phobia disorder and symptom counts derived from structured clinical interviews based on DSM-IV criteria.

The investigators expect to find significant reduction in social anxiety symptoms in the Treatment groups relative to the placebo control group. The investigators want to find out the relative efficacy of attention and interpretation oriented treatments and the combination of the two.

Conditions

  • Social Phobia

Interventions

BEHAVIORAL

Attention Bias Modification Treatment (ABMT)

Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.

BEHAVIORAL

Interpretation Bias Modification (IBM)

Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.

BEHAVIORAL

Control Condition

Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.

BEHAVIORAL

Attention and Interpretive biases modification (CBM)

Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.

Sponsors & Collaborators

  • Tel Aviv University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01503151 on ClinicalTrials.gov